Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seribantumab + Exemestane in ER+/PR+ Her2- Breast Cancer
NCT01151046Phase 2Completed
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Jun 2010
- Primary completion
- Jun 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing MM-121 + Exemestane with Placebo + Exemestane (2 arms). Primary endpoint: Progression Free Survival at 79.1 weeks. Started Jun 2010; status: completed.
02
Drugs
seribantumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01151046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01151046.